Sean Lee
Stock Analyst at HC Wainwright & Co.
(4.12)
# 431
Out of 4,765 analysts
72
Total ratings
36.99%
Success rate
21.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MYO Myomo | Maintains: Buy | $7.5 → $9.5 | $5.07 | +87.38% | 5 | Mar 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $22 → $40 | $29.49 | +35.64% | 9 | Jan 22, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Buy | $11 | $4.50 | +144.44% | 2 | Jan 14, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Buy | $20 | $9.27 | +115.75% | 11 | Jan 14, 2025 | |
| VSTM Verastem | Reiterates: Buy | $7 | $7.21 | -2.91% | 12 | Dec 19, 2024 | |
| PSTV Plus Therapeutics | Reiterates: Buy | $8 | $0.75 | +966.67% | 10 | Nov 26, 2024 | |
| CTSO Cytosorbents | Reiterates: Neutral | $1 | $1.07 | -6.54% | 11 | Nov 11, 2024 | |
| KZIA Kazia Therapeutics | Reiterates: Buy | $20 | $0.96 | +1,983.33% | 4 | Jul 12, 2024 | |
| CASI CASI Pharmaceuticals | Maintains: Buy | $12 → $6 | $2.07 | +189.86% | 7 | May 15, 2024 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $30 | $0.91 | +3,204.33% | 1 | Dec 5, 2022 |
Myomo
Mar 12, 2025
Maintains: Buy
Price Target: $7.5 → $9.5
Current: $5.07
Upside: +87.38%
Monopar Therapeutics
Jan 22, 2025
Maintains: Buy
Price Target: $22 → $40
Current: $29.49
Upside: +35.64%
Corvus Pharmaceuticals
Jan 14, 2025
Reiterates: Buy
Price Target: $11
Current: $4.50
Upside: +144.44%
Alphatec Holdings
Jan 14, 2025
Reiterates: Buy
Price Target: $20
Current: $9.27
Upside: +115.75%
Verastem
Dec 19, 2024
Reiterates: Buy
Price Target: $7
Current: $7.21
Upside: -2.91%
Plus Therapeutics
Nov 26, 2024
Reiterates: Buy
Price Target: $8
Current: $0.75
Upside: +966.67%
Cytosorbents
Nov 11, 2024
Reiterates: Neutral
Price Target: $1
Current: $1.07
Upside: -6.54%
Kazia Therapeutics
Jul 12, 2024
Reiterates: Buy
Price Target: $20
Current: $0.96
Upside: +1,983.33%
CASI Pharmaceuticals
May 15, 2024
Maintains: Buy
Price Target: $12 → $6
Current: $2.07
Upside: +189.86%
Akari Therapeutics,
Dec 5, 2022
Initiates: Buy
Price Target: $30
Current: $0.91
Upside: +3,204.33%